# Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole

> **NCT01468558** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MAP0004
- **DRUG:** IV DHE
- **DRUG:** Ketoconazole

## Key facts

- **NCT ID:** NCT01468558
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468558, "Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01468558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*